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Abstract
Prostaglandin E2  (PGE2) plays an important role in bone
development and metabolism. To interfere therapeutically in the
PGE2  pathway, however, knowledge about the involved
enzymes (cyclooxygenases) and receptors (PGE2 receptors) is
essential. We therefore examined the production of PGE2 in
cultured growth plate chondrocytes in vitro and the effects of
exogenously added PGE2 on cell proliferation. Furthermore, we
analysed the expression and spatial distribution of
cyclooxygenase (COX)-1 and COX-2 and PGE2 receptor types
EP1, EP2, EP3 and EP4 in the growth plate in situ and in vitro.
PGE2 synthesis was determined by mass spectrometry, cell
proliferation by DNA [3H]-thymidine incorporation, mRNA
expression of cyclooxygenases and EP receptors by RT-PCR on
cultured cells and in homogenized growth plates. To determine
cellular expression, frozen sections of rat tibial growth plate and
primary chondrocyte cultures were stained using
immunohistochemistry with polyclonal antibodies directed
towards COX-1, COX-2, EP1, EP2, EP3, and EP4. Cultured
growth plate chondrocytes transiently secreted PGE2 into the
culture medium. Although both enzymes were expressed in
chondrocytes in vitro and in vivo, it appears that mainly COX-2
contributed to PGE2-dependent proliferation. Exogenously
added PGE2 stimulated DNA synthesis in a dose-dependent
fashion and gave a bell-shaped curve with a maximum at 10-8 M.
The EP1/EP3 specific agonist sulprostone and the EP1-
selective agonist ONO-D1-004 increased DNA synthesis. The
effect of PGE2 was suppressed by ONO-8711. The expression
of EP1, EP2, EP3, and EP4 receptors in situ and in vitro was
observed; EP2 was homogenously expressed in all zones of the
growth plate in situ, whereas EP1 expression was
inhomogenous, with spared cells in the reserve zone. In cultured
cells these four receptors were expressed in a subset of cells
only. The most intense staining for the EP1 receptor was found
in polygonal cells surrounded by matrix. Expression of receptor
protein for EP3 and EP4 was observed also in rat growth plates.
In cultured chrondrocytes, however, only weak expression of
EP3 and EP4 receptor was detected. We suggest that in
growth plate chondrocytes, COX-2 is responsible for PGE2
release, which stimulates cell proliferation via the EP1 receptor.
Introduction
Prostaglandins, especially prostaglandin E2 (PGE2), play an
important role in bone and cartilage metabolism. Although
PGE2 was initially described as a potent bone-resorbing sub-
stance [1], several studies have demonstrated its activity in
bone-forming processes [2,3]. In osteoblast-like cells, endog-
enous PGE2 was shown to affect proliferation and differentia-
tion by stimulation of DNA synthesis and alkaline phosphatase
activity [4]. An interesting aspect in the investigation of the
function of prostaglandins in cartilage or bone tissue is their
possible role in the growth plate. This special cartilage tissue
is responsible for the endochondral ossification of long bones
and represents all differentiation steps in distinguishable lay-
ers, from undifferentiated reserve zone cells to proliferative
and hypertrophic chondrocytes, which initiate cartilage miner-
alisation. Due to this complex structure of the growth plate,
cellular effects of prostaglandins on growth plate chondro-
cytes have been examined using various in vitro systems.
Col = collagen; COX = cyclooxygenase; DMEM = Dulbecco's modified Eagle's medium; EP = prostaglandin E receptor; FCS = fetal calf serum; 
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PGE2  elicits differentiation of chondrocytes, as previously
shown for the chondrocyte cell line RCJ3.1C5.18 [5] and rat
growth plate chondrocytes [6]. In the latter, the effect of PGE2
was mediated by cAMP and protein kinase C. Furthermore,
PGE2 also makes an important contribution to cartilage forma-
tion and promotes DNA and matrix synthesis in growth plate
chondrocytes [7]. In addition to various findings in vitro, the
physiological role of prostaglandins was clarified by its stimu-
lating effect on bone formation and by the increase in bone
mass after systemic administration of PGE2 to infants [8] and
animals [9]. Furthermore, local administration of PGE2 resulted
in osteogenesis in situ [10,11].
The rate-limiting step for the synthesis of PGE2 and other pros-
taglandins is the conversion of arachidonic acid to prostaglan-
din endoperoxide by cyclooxygenase (COX), which exists in
two isoforms, COX-1 and COX-2 [12]. These enzymes are dif-
ferentially regulated. Previous in vitro analysis demonstrated
the functional importance of COX-1 for proliferation, differen-
tiation and matrix production in cultured growth zone chondro-
cytes [13]. In various chondrocyte cell models, as well as in
fracture callus formation, COX-2 may also be important for
prostaglandin synthesis [14]. Moreover, the expression of
COX-2 is regulated by different stimuli, such as tumour necro-
sis factor-α [15] or shear stress [16]. The induction of COX-2
is regarded as an important step in inflammatory situations.
COX-1 and COX-2 are expressed in inflamed bone tissue [17]
and COX inhibitors are extensively used in the treatment of
rheumatoid arthritis. However, inadequate information is avail-
able on in situ expression of both COX-1 and COX-2 within
the growth plate to correlate in vitro findings with the in situ
situation.
PGE2, the principal product of bone prostaglandin synthesis,
acts locally on target cells by binding to prostaglandin E (EP)-
type G protein-coupled receptors. Four different EP receptors
are known, which are linked to different intracellular signal
transduction pathways [18]. The EP1 receptor is coupled to
intracellular Ca2+ mobilization, while the EP2 and EP4 recep-
tors increase intracellular cAMP accumulation. By contrast,
EP3 inhibits intracellular cAMP accumulation. Regarding bone
formation and bone resorption, the EP4 receptor has been
shown to be essential in terms of PGE2 action in bone [19].
Recently, the EP2 and EP4 receptors were shown to be
required for PGE2-dependent chondrocyte differentiation
[20]. In previous studies, we demonstrated that stimulation of
growth plate chondrocyte proliferation by both calciotropic
hormones, 1,25 (OH)2D3 and parathyroid hormone, is depend-
ent on an increase in intracellular calcium and activation of pro-
tein kinase C [21]. On the other hand, an increase in
intracellular cAMP concentration was without any effect on
proliferation [21], but was able to stimulate matrix synthesis
[22]. In the present study, we were interested in whether
PGE2 acts in a proliferative and stimulatory fashion on growth
plate chondrocyte function. We therefore investigated the
effects of PGE2  and prostaglandin receptor agonists and
antagonists on cultured growth plate chondrocytes. Further-
more, we analysed the expression and spatial distribution of
COX-1 and COX-2 and the PGE2 receptors EP1, EP2, EP3,
and EP4 in the growth plate and compared this profile with
their expression in cultured growth plate chondrocytes in
order to give innovative insights into in situ -in vitro correla-
tions.
Materials and methods
Materials
Polyclonal rabbit antibodies against the EP1, EP2, EP3 and
EP4 receptors and COX-1 and COX-2 were described previ-
ously [23,24]. Polyclonal rabbit antibodies against collagen
(Col) type I and type II were purchased from Biotrend Chemi-
cals GmbH (Cologne, Germany). Monoclonal anti-collagen
type X antibody (mouse) was from Quartett (Berlin, Germany).
All other antibodies used were obtained from DAKO (Glos-
trup, Denmark). DNase (10 U/µl) for cartilage digestion was
from Amersham Pharmacia Biotech (Piscataway, NY, USA)
and CaCl2 was from Serva (Heidelberg, Germany). FCS and
culture dishes were from Greiner (Frickenhausen, Germany),
and culture media were obtained from PAA GmbH (Linz, Aus-
tria). Butaprost, misoprostole, sulprostone and PGE2 were
purchased from Cayman Chemical Company (Ann Arbor,
Michigan, USA). Ligands for the PGE2 receptors (ONO D1-
004, ONO AE1-259-001, ONO AE-248, ONO AE1-329, and
ONO-8711) have been described previously [25-27] and
were kindly provided by Dr Maruyama (ONO Pharmaceuticals,
Osaka, Japan). PicoGreen for double-stranded (ds)DNA quan-
tification was obtained from Mobitec (Göttingen, Germany).
Gene Amp RNA-PCR kit, DNA Polymerase (Ampli taq Gold),
reverse transcriptase (MuLV RT) and oligo d(T)16 were pur-
chased from Perkin Elmer, Roche Molecular Systems Inc.
(Branchburg, NJ, USA). Other chemicals were of p.a. grade
and purchased from Merck (Darmstadt, Germany), Gibco BRL
Life Technologies (Karlsruhe, Germany) or Sigma Aldrich
Chemistry (Steinheim, Germany).
Cell culture
Isolation of chondrocytes
Chondrocytes were isolated and cultured as described earlier
by Benya and Shaffer [28] and modified according to Klaus
and colleagues [21]. Briefly, femurs of up to four week old
Sprague Dawley rats (60 to 80 g each) were dissected. The
epiphyseal growth plate of the tibiae was separated by clean-
ing the cartilage plate of muscular tissue, periosteum and peri-
chondrium. The proximal epiphysis was divided by a
transverse cut with a sharp scalpel, and the cartilage plate was
separated distally from the calcification zone of the tibial met-
aphysis. Isolated growth plates were digested for 3 hours at
37°C by collagenase (0.12% w/v) and DNase (0.02% w/v) in
5 ml of serum free F12/DMEM medium. After thorough wash-
ing, cells were counted using a Neubauer chamber. Viability,
examined by trypan blue exclusion, was > 95%.Available online http://arthritis-research.com/content/8/3/R78
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Monolayer cultures
Chondrocytes were cultured in flasks, 96-well-plates or 2-well
cell-tissue-chambers containing F12/DMEM 1/1 medium sup-
plemented with 10% FCS, 10 mM HEPES, 2 mM pyruvate, 2
mM L-glutamine, 0.7 µM CaCl2, 10 mg/ml penicillin/strepto-
mycin and L-cysteine. Ionized calcium measured by a calcium-
sensitive electrode was 1.2 mmol/l. During the first four days
of cell culturing the serum substitute Ultroser-G (1%) was
added to the medium. From day 5 on, β-glycerophosphate (10
mM) and L-thyroxine (100 µg/µl), as well as ascorbic acid (5
to 60 µg/ml) from day 11 on, were added to the culture
medium. Medium was changed every 48 hours and cells
became confluent within 6 to 12 days.
Assay of cell proliferation: semiquantitative dsDNA 
determination
Primary cultures of chondrocytes were transferred to 96-well-
plates in serum-free medium without L-thyroxine, which is
reported to exert antiproliferative effects [29]. Cell cycles were
synchronised for 24 hours as described earlier [21].
PGE2, EP receptor agonists, or vehicle were added with fresh
medium, supplemented with 10% FCS and cells were stimu-
lated for 24 or 48 hours. Incubation was stopped by aspiration
of the supernatants and the culture plates were frozen at -
80°C for 1 hour. Thereafter, cells were thawed and incubated
with 200 µl staining solution (containing 2.5 µl/ml PicoGreen)
for 10 minutes under light protection. Optical density was
determined using a plate reader (excitation/emission, 485 nm/
530 nm). Experiments were run with four to six parallel
aliquots.
Assay of cell proliferation: [3H]-thymidine incorporation
Incorporation of [3H]-thymidine was determined in serum-free
cultures as described previously [21]. Cells were synchro-
nised in serum-free medium for 24 hours. Thereafter, medium
was changed to F-12/DMEM with 0.2% (w/v) bovine serum
albumin and the substances or vehicles were added. Cells
were incubated for 48 hours and 2 µCi [3H]-thymidine were
added to each well 3 hours before stopping the incubation.
Reverse transcriptase-polymerase chain reaction
Total RNA was isolated from first passage monolayer cultures
of chondrocytes and from two to eight freshly isolated epiphy-
seal growth plates that were pulverised in liquid nitrogen. After
DNase digestion, 1.2 µg (from cells) or 0.5 µg (from tissue)
RNA was transcribed into cDNA using oligo dT. RT-PCR was
performed for EP1, EP2, EP3, EP4, COX-1, COX-2, Col I, Col
Table 1
Primers used for RT-PCR
mRNA Sequence of primer Product (bp) Accession numbers
EP-1 5' -GCT GTA CGC CTC GCA TCG TGG-3'
5' -GTG TTT CGA GCA TCC CAT GTA TCT-3'
404 NCBI:D16338
EP-2 5' -GAA CGC TAC CTC TCC ATC GG-3'
5' -TGA TGG TCA TAA TGG-3'
415 NCBI:D50589
COX-1EP-3 5' -GTTTGGTCTG GCGTCTTAGA AC-3'
5' -CTTGGAACAG GACCTTCTGA GT-3'
5' -TTTGCCTCCGCCTTCGCCTG-3'
5' -AGCAGCAGATAAACC-3'
399,359 U03388 NCBI:D14869
COX-2EP-4 5' -AATGAGTACC GCAAA-3'
5' -ATCTAGTCTG GAGCGGGAGG-3'
5' -TGCTCATCTGCTCCATTCCGC-3'
5' -ATGCGAACCTGGAAG-5'
420,407 NM011198NCBI:D28860
Col ICOX-1 5' -TGGTGACAAG GGTGAGACAG-3'
5' -TGAGGCAGGA AGCTGAAGTC-3'
5' -GTTTGGTCTG GCGTCTTAGA AC-3'
5' -CTTGGAACAG GACCTTCTGA GT-3'
329,399 Z78279NCBI:U03388
Col IICOX-2 5' -CTCCAGGTGT GAAGGGTGAG-3'
5' -GAACCTTGAG CACCTTCAGG-3'
5' -AATGAGTACC GCAAA-3'
5' -ATCTAGTCTG GAGCGGGAGG-3'
261,420 NM012929NCBI:NM011198
Col XI 5' -TGCCTCTTGT CAGTGCTAAC C-3'
5' -GCGTGCCGTT CTTATACAGG-3'
5' -TGGTGACAAG GGTGAGACAG-3'
5' -TGAGGCAGGA AGCTGAAGTC-3'
248
329
AJ131848NCBI:Z78279
β-actinCol II 5' -CATCACCATT GGCAATGAGC G-3'
5' -CTAGAAGCAT TTGCGGTCGG AC-3'
5' -CTCCAGGTGT GAAGGGTGAG-3'
5' -GAACCTTGAG CACCTTCAGG-3'
403,261 NM031144NCBI:NM012929
Col X 5' -TGCCTCTTGT CAGTGCTAAC C-3'
5' -GCGTGCCGTT CTTATACAGG-3'
248 NCBI:AJ131848
β-actin 5' -CATCACCATT GGCAATGAGC G-3'
5' -CTAGAAGCAT TTGCGGTCGG AC-3'
403 NCBI:NM031144
Col, collagen; COX, cyclooxygenase; EP, prostaglandin E receptor.Arthritis Research & Therapy    Vol 8 No 3    Brochhausen et al.
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II, Col X and β-actin. Primers used in this study are listed in
Table 1. The amplification profile consisted of denaturation at
95°C for 30 seconds, annealing at 54°C (EP receptors and
COX) or at 57°C (collagens) for 45 seconds and extension of
DNA at 72°C for 30 seconds after a 10 minute denaturation
step at 95°C. When using RNA from bone tissue, the number
of cycles were 40 for the EP receptors and 45 for the collagen
types, and when using RNA from cultured chondrocytes, 35
cycles and 30 cycles, respectively, were performed. The
amplification products of 10 µl of each PCR reaction were
separated on a 1.8% agarose gel, stained with ethidium bro-
mide, and visualised by ultraviolet irradiation. Identification of
amplification products was determined by size and dideoxy
sequencing.
Immunohistochemistry
For immunohistochemistry, the epiphyseal plate with neigh-
bouring bony metaphysis and epiphysis including the knee
joint were dissected. The isolated tissue was immediately fro-
zen in isopentane at -80°C. For detection of EP1, EP2, EP3,
EP4, COX-1, COX-2, Col II and Col X, the alkaline-phos-
phatase-anti-alkaline-phosphatase method was used accord-
ing to Cordell and colleagues [30] as modified by Bittinger
and colleagues [31]. Frozen sections (4 µm) were fixed in
paraformaldehyde (4%). Polyclonal rabbit antibodies against
EP1 (1:300), EP2 (1:200), EP3 (1:300), EP4 (1:300), COX-
1 (1:100), COX-2 (1:100) and Col II (1:800) as well as a mon-
oclonal mouse antibody against Col X (1:200) were incubated
for 16 hours at 4°C. After staining, these sections were coun-
ter-stained with hemalaun. For the antibodies directed against
the EP receptors, the following controls were performed.
Firstly, the primary antibody was omitted; under this condition
no staining was visible. Secondly, the antibodies were preab-
sorbed with the corresponding peptide against which they are
directed as described previously [24]; under this condition
staining was completely blocked.
Determination of PGE2
PGE2 was determined in cell supernatants as described previ-
ously [32].
Statistical analysis
Statistical analysis was carried out by t test or ANOVA as
appropriate. P values are < 0.05 or < 0.001.
Results
Collagen expression in cultured chondrocytes
To define the differentiation stage of cultured chondrocytes
we first studied the expression of various collagens. Col I is
typically expressed towards the metaphyseal zone, whereas
Col II is present in the proliferation zone and Col X in the hyper-
trophic zone. Proliferating cells express Col II and Col X is
strongly expressed after the transition from pre-hypertrophic,
Figure 1
Collagen protein and mRNA expression in cultured rat growth plate  chondrocytes Collagen protein and mRNA expression in cultured rat growth plate 
chondrocytes. Isolated rat chondrocytes were cultured until confluency. 
(a) Protein expression for collagen I, II and X was studied in cultured 
chondrocytes with type-specific antibodies and using the alkaline-phos-
phatase-anti-alkaline-phosphatase method. Collagen type I was 
expressed in the majority of the cultured cells. Collagen II was strongly 
detected in chondrocytes of polygonal shape, representing more than 
80% of the cultured cells. In cultured chondrocytes, no reactivity 
towards the collagen X antibody was observed. The antigens of the 
antibodies are indicated below the figures. (b) mRNA expression of the 
various collagen types. PCR analysis revealed expression of mRNA for 
collagen (Coll) I and collagen II and only marginal expression of colla-
gen X mRNA.
Figure 2
Cyclooxygenase (COX) expression in cultured rat growth plate  chondrocytes and in the growth plate Cyclooxygenase (COX) expression in cultured rat growth plate 
chondrocytes and in the growth plate. Expression of mRNA for COX-1 
and COX-2 was analysed by reverse transcription RT-PCR. β-actin was 
used as positive control. Both growth plate tissue and cultured 
chondrocytes express mRNA for COX-1 and COX-2. bp, base-pairs.Available online http://arthritis-research.com/content/8/3/R78
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proliferating chondrocytes to hypertrophy. Accordingly, we
observed staining for Col II mainly in the proliferative zone and
Col X in the hypertrophic zone of the growth plate (data not
shown). In cultured chondrocytes, we observed strong stain-
ing for Col II in more than 90% of the cells but no antigenicity
towards the anti-Col X antibody (Figure 1a). In addition, Col I
was expressed in cultured chondrocytes. In support of this
observation, we obtained strong amplification with specific
primers for Col I and Col II, but weak amplification with
oligonucleotides specific for Col X in the cultured chondro-
cytes (Figure 1b). This finding is in keeping with the chondro-
cyte phenotype, as most cells are in the proliferative stage.
PGE2 production and COX-1 and COX-2 expression
Isolated rat growth plate chondrocytes released PGE2 tran-
siently into the supernatants. Within the first 48 hours, a four-
fold increase in PGE2 concentration was observed (Table 2).
After six days of culture, however, PGE2 release by subconflu-
ent, slowly proliferating cells was reduced almost to baseline
levels.
To determine the COX isoform involved in PGE2 synthesis, we
analysed mRNA and protein expression of COX-1 and COX-2
in growth plates as well as in cultured chondrocytes. Regard-
ing mRNA expression, both growth plates and cultured
chondrocytes expressed COX-1 and COX-2 mRNA (Figure
2). Isoform-specific antibodies were used to determine COX
distribution in rat growth plate tissue and in cultured rat
chondrocytes. To ensure specificity, the following control
experiments were performed: firstly, the primary antibody was
omitted; and secondly, for COX-2, the antibodies were preab-
sorbed with the corresponding peptide against which they are
directed, as described previously [24]. Under these condi-
tions, no staining was visible (data not shown). On the protein
level, growth plates as well as cultured chondrocytes
expressed both COX isoforms (Figure 3). Growth plate
chondrocytes in situ showed intracellular expression of both
COX isoforms. Regarding the spatial distribution of COX
expression in the different zones of the growth plate, a dispa-
rate expression pattern of COX-1 and COX-2 was observed.
COX-1 stained chondrocytes in all zones of the growth plate
strongly and homogenously, whereas COX-2 appeared to be
only moderately expressed in the reserve zone cells but
strongly expressed in the other zones of the growth plate. In
cultured chondrocytes, COX-1 expression appeared to be
predominantly in the perinuclear region, whereas COX-2
expression dominated in the dendritic processes of all cells.
To further investigate the role of the COX isoform in chondro-
cyte proliferation, we blocked both isoform activities with the
unspecific inhibitor indomethacin and each of the isoforms
with the specific COX-1 inhibitorSC-560, or the COX-2 inhib-
itor SC-236. Indomethacin suppressed chondrocyte prolifera-
tion as assessed by thymidine incorporation (Figure 4). A
similar extent of proliferation inhibition was achieved by the
addition of the COX-2 inhibitor SC-236 but not SC-560. This
indicates that COX-2 is primarily important for chondrocyte
proliferation.
Figure 3
Cyclooxygenase (COX) expression in rat growth plate chondrocytes in  vitro and in situ Cyclooxygenase (COX) expression in rat growth plate chondrocytes in 
vitro and in situ. Protein expression of COX-1 and COX-2 was studied 
using isoform-specific antibodies. Both COX isoforms could be 
detected in all zones of the growth plate. In cultured growth plate 
chondrocytes, COX-1 was expressed in all cultured chondrocytes with 
high intensity in paranuclear areas (marked by arrow). COX-2 protein 
was detected in extranuclear regions as well as in cell processes 
(marked by arrow) of a sub-population of the cultured cells only. r, 
reserve zone; p, proliferative zone; h, hypertrophic zone.
Figure 4
Proliferation assay with selective and unselective cyclooxygenase  (COX) inhibitors Proliferation assay with selective and unselective cyclooxygenase 
(COX) inhibitors. The effect of selective and unselective COX inhibitors 
on chondrocyte proliferation was assessed by [3H]-thymidine incorpo-
ration. Subconfluent chondrocytes were synchronized in serum-free 
medium for 24 hours. Medium was renewed and the indicated inhibi-
tors were added for 24 hours: indo, 50 µM indomethacin; SC-560, 10 
µM; SC-236, 10 µM. Data are given as mean ± standard error of the 
mean, n = 6; *p value < 0.05.Arthritis Research & Therapy    Vol 8 No 3    Brochhausen et al.
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Effect of PGE2 and analogues on proliferation of growth 
plate chondrocytes
To analyse whether PGE2 might stimulate cell proliferation in
an autocrine or paracrine manner, we studied the effect of
exogenously added PGE2 in cultured rat chondrocytes. Cell
cycles were synchronized by 24 hour starving. DNA synthesis
was determined by [3H]-thymidine incorporation and DNA
content by fluorescence spectroscopy. In a bell-shape man-
ner, PGE2 stimulated DNA synthesis with a maximum at 10 nM
PGE2 (Figure 5a). The proliferative effect of PGE2 was also
observed by semiquantitative determination of DNA content
(Figure 5b).
To define the EP receptor(s) involved in PGE2 signalling in this
experimental setting, we used agonists for the various EP
receptor types. Stimulation with the EP1/EP3 receptor agonist
sulprostone resulted in a significant increase of chondrocyte
[3H]-thymidine incorporation, whereas the EP2/EP3 receptor
agonist misoprostole had an intermediate effect and the EP2
agonist butaprost exerted no effect (Figure 6a). These obser-
Figure 5
Effect of prostaglandin E2 (PGE2) on chondrocyte proliferation Effect of prostaglandin E2 (PGE2) on chondrocyte proliferation. (a) Pro-
liferation of cultured chondrocytes was determined by [3H]-thymidine 
incorporation. Subconfluent chondrocytes were synchronized in serum-
free medium for 24 hours. Medium was renewed and PGE2 or solvent 
was added in the indicated concentrations for 24 hours. Data are pre-
sented as mean ± standard error of the mean, n = 5. (b) Relative quan-
tification of DNA in cultured chondrocytes was used as a measure for 
proliferation. Chondrocytes were grown in 96-well-plates until subcon-
fluency. After synchronization, PGE2 or solvent was added for 24 hours. 
Thereafter, medium was aspirated, DNA was extracted by freeze-thaw-
ing and 200 µl of the staining solution (containing a fluorescent nucleic 
acid stain) were added and DNA-bound fluorophore was determined 
by fluorescence spectroscopy, expressed as OD at 530 nm. Data are 
presented as mean ± standard error of the mean of four parallel experi-
ments, given as percent of the control. Excitation of the control was 
14,705 ± 2,675 after 24 hours. *p value < 0.05.
Figure 6
Effect of prostaglandin E (EP) receptor ligands on proliferation of cul- tured chondrocytes Effect of prostaglandin E (EP) receptor ligands on proliferation of cul-
tured chondrocytes. (a) Unselective and selective EP receptor agonists 
were administered to cultured chondrocytes. Subconfluent chondro-
cytes were synchronized in serum-free medium for 24 hours and EP 
receptor agonists were added for 24 hours. Proliferation was assessed 
by [3H]thymidine incorporation. C, control; Sul, 1 µM sulprostone; 
Miso, 1 µM misoprostole; But, 1 µM butaprost; EP1A, 4 µM ONO-D1-
004; EP2A, 0.1 µM ONO-AE1-259-01; EP3A, 0.1 µM ONO-AE-248; 
EP4A, 0.1 µM ONO-AE1-329. Data are given as mean ± standard 
error of the mean, n = 5. *P value < 0.05. (b) To study EP1 function for 
cell growth, a EP1 receptor selective agonist and antagonist were 
added to cultured chondrocytes. Subconfluent chondrocytes were syn-
chronized in serum-free medium for 24 hours and EP1 receptor agonist 
(EP1A) or antagonist (EP1AN) combined with 10 nM prostaglandin E2 
were added for 24 hours in the presence of [3H]-thymidine. EP1A, 4 
µM ONO-D1-004; EP1AN, 1 µM ONO-8711. Data are given as mean 
± standard error of the mean, n = 5. *P value < 0.05.Available online http://arthritis-research.com/content/8/3/R78
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vations were further supported by the use of EP receptor sub-
type-specific ligands. The EP1 agonist ONO-D1-004, and to
a lesser extent the EP2 agonist ONO-AE1-259-01 and the
EP3 agonist ONO-AE-248, significantly increased [3H]-thymi-
dine incorporation whereas the EP4 selective agonist ONO-
AE1-329 exerted no effect. The proliferative activity of the EP1
agonist ONO-D1-004 was similar to maximal stimulation
achieved by PGE2. In support of this observation, the addition
of the selective EP1 antagonist ONO-8713 completely
blocked PGE2-induced proliferation (Figure 6b).
Expression of EP1 and EP2 receptors
The expression of the different EP receptors was studied at
the mRNA level by PCR and at the protein level by immunohis-
tochemistry. The specificity of the antibodies used was
assessed by omitting the first antibody and by preabsorbing
with the corresponding peptide against which the antibody
was generated. Under both conditions specific staining was
absent (data not shown). Growth plate tissue as well as cul-
tured chondrocytes showed expression of EP1 and EP2
receptor mRNA detected by reverse transcription-PCR (Fig-
ure 7). Regarding protein expression of the EP1 and EP2
receptors, the antibody against the EP2 receptor labelled all
zones of the epiphyseal growth plate in a homogeneous man-
ner. EP1 expression showed a different expression pattern,
with strong expression in the proliferative and hypertrophic
zone and only moderate expression in the reserve zone, occa-
sionally with EP1 negative cells (Figure 8). In cultured
chondrocytes, staining for EP1 was intense in confluent polyg-
onal cells, which were organised in a cobblestone pattern and
surrounded by matrix, whereas fibroblastic shaped cells were
only occasionally positive. The EP2 receptor protein was
expressed in distinct chondrocytes only. High expression was
detected in dividing cells and polygonal chondrocytes embed-
ded in matrix, whereas fibroblastic, and less differentiated
chondrocytes showed only marginal staining in a small number
of cells.
Expression of EP3 and EP4 receptors
Growth plate tissue as well as cultured chondrocytes showed
expression of EP3 and EP4 receptor mRNA, although the
amplification product for EP3 appeared to be less intense in
the chondrocytes (Figure 9). In growth plates, EP3 and EP4
receptors were expressed in all layers (Figure 10). In cultured
chondrocytes, a weak staining for both types of receptor was
visible (Figure 9). Only distinct cells, which represent less than
10%, exhibited a strong reaction against the antibodies used.
Discussion
The present study clearly demonstrates that growth plate
chondrocytes are capable of secreting PGE2. The effects of
PGE2 are mediated by G-protein-coupled receptors with dif-
ferent pathways of signal transduction. The present data show
Figure 7
Expression of EP1 and EP2 receptors in rat growth plates and in cul- tured chondrocytes at the mRNA level Expression of EP1 and EP2 receptors in rat growth plates and in cul-
tured chondrocytes at the mRNA level. Expression of mRNA for EP1 
and EP2 receptors was analysed by reverse transcription RT-PCR. β-
actin was used as a positive control. Both growth plate tissue and cul-
tured chondrocytes express mRNA for EP1 and EP2.
Figure 8
Immunohistochemical detection of EP1 and EP2 receptor in rat growth  plates and in cultured chondrocytes Immunohistochemical detection of EP1 and EP2 receptor in rat growth 
plates and in cultured chondrocytes. Protein expression of EP1 and 
EP2 receptor was studied using isoform-specific antibodies. The EP1 
receptor showed strong expression in the proliferative and hypertrophic 
zone but marginal expression in the reserve zone, with some negative 
cells (marked by arrow). In contrast, the EP2 receptor was distributed 
throughout the whole growth plate. In vitro the EP1 and EP2 receptors 
were only expressed in subpopulations. EP1 showed strong positivity in 
chondrocytes organised in a cobblestone pattern and surrounded by 
matrix, whereas fibroblastic-shaped cells were only occasionally and 
moderately positive for EP1. The highest expression for EP2 could be 
demonstrated in dividing cells and polygonal cells embedded in matrix 
(marked by arrow). In fibroblastic cells, only minimal to slight positivity 
was found in a small number of cells. Magnification 200 × . r, reserve 
zone; p, proliferative zone; h, hypertrophic zone.Arthritis Research & Therapy    Vol 8 No 3    Brochhausen et al.
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for the first time expression of COX-1 and COX-2, as well as
EP1, EP2, EP3 and EP4, in the intact growth plate in situ in
comparison with the expression in cultured growth plate
chondrocytes. COX enzymes are expressed in situ in a char-
acteristic spatial distribution: whereas COX-1 is homoge-
nously expressed in all zones of the growth plate, COX-2
showed moderate expression in the reserve zone and strong
expression in the other zones. Regarding EP receptor expres-
sion, EP1 expression in situ was mainly restricted to the prolif-
erative and hypertrophic zone. Contrasting with this, EP2, EP3
and EP4 receptors in situ were homogeneously expressed by
all chondrocytes, but in vitro by a subpopulation of cells only.
Collagen expression was analysed as a parameter of the phe-
notypic integrity of the chondrocytes and Col II and Col X are
expressed in specific maturation states. In our system, the dif-
ferentiation state of the majority of cells corresponded to cells
in the proliferative layer, as shown previously [33]. This is con-
firmed not only by the proliferative activity but also by the pro-
duction of Col II, and the lack of Col X, which is a specific
marker of late hypertrophic chondrocytes [34]. Col I is not
believed to be characteristically expressed in the growth plate
and costochondral cartilage, but rather in the superficial layer
of mandibular and articular cartilage [35]. Col I was also
detectable in our cultured cells, which indicates the presence
of 'de-differentiated' chondrocytes [28] in the absence of Col
X expression.
PGE2 is produced by COX, of which two isoforms – COX-1
and COX-2 – exist. However, its protein expression has not
been demonstrated previously in the growth plate, despite the
fact that secreted prostanoids, which were generated by
COX-1 and/or COX-2, were shown to modulate chondrocyte
proliferation and function in in vitro systems. These results can
only be extrapolated to the in situ situation if COX is expressed
in the intact growth plate. Using polyclonal antibodies to COX-
1 and COX-2, we were able to demonstrate COX-1 and COX-
2 immunoreactivity in growth plate chondrocytes. Paralleling
the in situ situation, both COX-1 and COX-2 mRNA as well as
COX-1 and COX-2 protein were expressed in cultured
chondrocytes. Concluding from the observed inhibitory effect
of the COX-2 inhibitor SC-236, but not of the COX-1 inhibitor
SC-560, on chondrocyte proliferation, we suggest that, at
least for the cultured chondrocytes, COX-2 is the responsible
enzyme driving PGE2 formation.
In our primary culture system, PGE2 stimulated DNA synthesis
in a bell-shaped manner, the strongest effect being observed
at concentrations that are higher than those physiologically
found in the circulation [36]. These results are in accordance
with studies by O'Keefe and colleagues [7] and Schwartz and
colleagues [6], describing a growth-stimulatory effect of PGE2
at similar concentrations. We speculate, therefore, that
secreted PGE2 could function as an autocrine/paracrine medi-
ator of chondrocyte proliferation. From in vitro studies it is well
known that PGE2may have different concentration-dependent
effects on cell proliferation and matrix synthesis. This implies
that local PGE2 concentrations in the various zones of the
growth plate may differ. In fact, bovine chondrocytes isolated
from the 'superficial zone' of the growth plate, that is, mainly
reserve zone cells, were shown to produce less PGE2 than
Figure 9
Expression of EP3 and EP4 receptor mRNA in rat growth plates and in  cultured chondrocytes Expression of EP3 and EP4 receptor mRNA in rat growth plates and in 
cultured chondrocytes. Expression of mRNA for EP3 and EP4 receptor 
was analysed by RT-PCR. β-actin was used as positive control. Both 
growth plate tissue and cultured chondrocytes express mRNA for EP3 
and EP4.
Figure 10
Immunohistochemical detection of EP3 and EP4 receptor proteins in  rat growth plates and in cultured chondrocytes Immunohistochemical detection of EP3 and EP4 receptor proteins in 
rat growth plates and in cultured chondrocytes. Protein expression of 
EP3 and EP4 receptor was studied in growth plate tissue and cultured 
chondrocytes using isoform-specific antibodies. The EP3 and EP4 
receptors were distributed throughout the whole growth plate. Cultured 
chondrocytes exhibited only weak reactivity towards the anti-EP anti-
bodies. Only a minor subpopulation of cells showed strong staining for 
EP3 receptor and EP4 receptor. Magnification: 200 × . r, reserve zone; 
p, proliferative zone; h, hypertrophic zone.Available online http://arthritis-research.com/content/8/3/R78
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proliferating and early hypertrophic cells isolated from the
'deep zone' [37].
The proliferative action of PGE2 was mimicked by sulprostone,
which was shown to selectively bind to EP1 and EP3 recep-
tors [38] and only a minor stimulatory effect was provoked by
misoprostole. Furthermore, a selective EP1 agonist provoked
a similar proliferative effect in rat cultured chondrocytes com-
pared to PGE2 and the growth-promoting effect of PGE2 could
be completely blocked by a specific EP1 antagonist. We con-
clude that PGE2 mediates its proliferative effect primarily via
the EP1 receptor. It has to be noted that a minor growth-pro-
moting effect was also seen by the addition of EP2, EP3 and
EP4 specific ligands. The minor growth-promoting effect
observed with the EP3 agonist might be due to the presence
of endogenously produced PGE2. EP3 receptor activation
causes a decrease in intracellular cAMP levels. We speculate
that in cultured chondrocytes, EP3 activation might promote
an EP1 signalling pathway, triggered by endogenously formed
PGE2, by ablation of cAMP, the opponent of the Ca2+ signal-
ling pathway. Alternatively, it has been shown that different
splice variants do exist for the EP3 receptor, which in part may
evoke a phosphatidyl-inositol response [18]. However, we can
not exclude that different subpopulations within our cell cul-
ture system are regulated in a different way by PGE2, as we
did not observe a homogenous expression of the different EP
receptors in the cultured chondrocytes. Differences in respon-
siveness to PGE2 has, for example, also been reported for
mouse chondroprogenitors and chondrocytes [39].
The second messenger of the EP1 receptor is free ionised
intracellular calcium [40]. An increase of intracellular calcium
was shown to be necessary for chondrocyte proliferation in
response to the calciotropic hormones parathormone and
1,25(OH)2D3 [21,41]. The latter is thought to stimulate cell
growth via generation of PGE2 [42]. To our knowledge, an
increase of intracellular calcium in response to PGE2 has not
been measured in growth plate chondrocytes. Contrasting
with this hypothesis, PGE2 was found to have no effect on
intracellular calcium in cultured articular bovine cartilage cells
[43].
Corresponding to the proposed proliferative action of PGE2
via the EP1 receptor, this receptor could be demonstrated at
the mRNA and protein levels not only in vitro but also in situ.
In the intact growth plate we observed a strong EP1 receptor
immunoreactivity in proliferative and hypertrophic chondro-
cytes, but not in reserve zone cells. This is in line with the pro-
liferative effect of PGE2 mediated via the EP1 receptor. In
vitro, EP1 was expressed in all cells, although the intensity var-
ied. Because in our culture system proliferative cells repre-
sented the majority of chondrocytes, the ubiquitous
expression of EP1 receptor in vitro was in contrast to the in
situ situation. This discrepancy indicates that extrapolation of
the in vitro data to the in situ situation should be done with
caution.
In addition, the EP2 receptor also showed a different expres-
sion pattern in situ and in vitro. The EP2 receptor was not uni-
formly detectable in vitro, although in situ all cells were
positive. The highest expression was observed in dividing
cells. It can be concluded from our data that EP2 receptor sig-
nalling also contributes to cell growth. The inhomogenous
expression of EP2 in cultured chondrocytes may explain the
lower proliferative effect achieved by the specific EP2 agonist.
EP2 receptor expression has also been described in cultured
articular chondrocytes [43] and fourth passage reserve zone
cells [44]. In the latter, PGE2 stimulated intracellular cAMP,
which resulted in increased matrix synthesis. In a chondrocyte
cell line, established from articular cartilage of p53-/- mice, the
EP2 receptor was identified as the major PGE2 receptor [45].
In this cell line, EP2 agonists evoked cAMP generation and
promoted cell growth. In articular chondrocytes, PGE2 proba-
bly mediates its proliferative effect primarily via the EP2 recep-
tor whereas in growth plate chondrocytes the EP1 receptor is
dominant for PGE2-dependent growth. EP2 and EP4 recep-
tors may also be involved in chondrogenesis [39]. In limb bud
mesenchymal cells, all four types of EP receptor are expressed
and EP2 and EP4 receptor activation of cAMP metabolism
was suggested to drive mesenchymal stem cells to chondro-
genesis. We observed a weak expression of the EP4 receptor
in our cultured chondrocytes. Most likely, EP receptors, and
especially the EP4 type, are expressed depending on the cell
differentiation state in culture. By contrast, in the growth plate
tissue of the rat we observed EP4 expression in all layers. In a
recent study, Miyamoto and colleagues [20] showed that the
EP2 receptor promotes differentiation and synthesis of Col II
and proteoglycans in cultured bovine growth plate cells. This
effect was dependent on co-stimulation of the EP4 receptor;
however, in rat, the EP4 receptor was not detected, at least in
fourth passage chondrocytes [46]. In view of these results, a
role for the EP2 receptor in chondrocyte differentiation can be
hypothesised. The differentiation-dependent expression of EP
receptors might explain the contradictory results obtained in
studies investigating the effects of PGE2. This indicates the
crucial role played by species and culture conditions used in
the various in vitro systems. According to our in vivo data, all
Table 2
Release of PGE2 into the supernatant of cultured rat 
chondrocytes
Incubation time PGE2 (µg/ml) Proliferation status
0 120 ± 20
2 days 530 ± 270a Rapidly proliferating
6 days 150 ± 30 Slowly proliferating
Chondrocytes were seeded in culture plates and fresh medium was 
added. At different time points supernatant was collected and 
analyzed for prostaglandin E2 (PGE2) content (n = 6; ap < 0.01 
versus day 0).Arthritis Research & Therapy    Vol 8 No 3    Brochhausen et al.
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types of EP receptors appeared to be expressed. Taking into
account that the different EP receptors are coupled to differ-
ent intracellular signalling pathways, we expect that other
mechanisms, such as receptor activation, modulation of ligand
affinity or selective access of PGE2 to the necessary receptor
type, are involved in ensuring a coordinated action of PGE2 in
growth plate physiology.
Conclusion
Cultured growth plate chondrocytes synthesized PGE2. Exog-
enous PGE2 stimulation had a proliferating-inducing effect in a
dose-dependent manner on cultured growth plate chondro-
cytes via the EP1 receptor, which could be mimicked by EP
agonists such as sulprostone and ONO-D1-004. The prolifer-
ating effects could be blocked by the EP1 antagonist ONO-
8713.
Further analyses of the physiological and pathophysiological
roles of EP1 and EP2, especially in chronic inflammatory dis-
orders, are needed. From a therapeutic point of view, the long
term effects of COX inhibitors and EP antagonists with
respect to the integrity of the growth plate in the paediatric
population is of special interest. Growth plate chondrocytes
express COX-1, COX-2 and EP1, EP2, EP3, and EP4 in situ
and in vitro with markedly different expression patterns. There-
fore, the extrapolation from in vitro data to the in situ situation
and the interpretation regarding physiological processes must
be done with caution.
With respect to the possibilities for cartilage regeneration in
the context of tissue engineering of bone and cartilage, the
present data open interesting new aspects for optimising the
seeding of scaffolds via stimulation of cell proliferation by
PGE2 or EP1 ligands; at present, this is under investigation.
The analysis of arachidonic metabolites in the growth plate in
vitro and in situ presents a wide scope for further investiga-
tions with pathophysiological, therapeutic and regenerative
end points.
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